EMA: Q&A Update; Expected studies for Quetiapine PR Tablets [BE/BA News]

posted by viveksraut – India, 2018-08-06 12:42 (986 d 07:20 ago) – Posting: # 19153
Views: 5,128

Dear all,

This is with reference to the point no. 14 (Quetiapine Lambda) of “Questions & Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP), EMA/618604/2008 Rev. 13” document published by EMA on 19 November 2015 )” to address specific questions in relation to pharmacokinetic evaluations and particularly the requirements and assessment of bioequivalence studies.

From the PKWP response to the point no. 14 question I understand the following;
So if applicant is developing generic version of Quetiapine prolonged release tablets and intended strengths are 25mg, 100mg, 200mg and 300 mg. Then in view of the PKWP response on this product and taking into account the guidance on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), 20 Nov 2014, what are the studies expected by EMA for this product ? Your opinion please on this.

Regards : Vivek

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,508 registered users;
online 14 (0 registered, 14 guests [including 2 identified bots]).
Forum time: Sunday 20:03 UTC (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5